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BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease with an 
emerging genetic basis. Heterozygous mutations in the gene encoding the bone 
morphogenetic protein receptor type 2 (BMPR2) are the commonest genetic 
cause of PAH, whereas biallelic mutations in the eukaryotic translation initiation 
factor 2 alpha kinase 4 gene (EIF2AK4) are described in pulmonary veno-occlusive 
disease/pulmonary capillary hemangiomatosis. Here, we determine the frequency 
of these mutations and define the genotype-phenotype characteristics in a large 
cohort of patients diagnosed clinically with PAH.
METHODS: Whole-genome sequencing was performed on DNA from patients 
with idiopathic and heritable PAH and with pulmonary veno-occlusive disease/
pulmonary capillary hemangiomatosis recruited to the National Institute of Health 
Research BioResource–Rare Diseases study. Heterozygous variants in BMPR2 and 
biallelic EIF2AK4 variants with a minor allele frequency of <1:10 000 in control 
data sets and predicted to be deleterious (by combined annotation-dependent 
depletion, PolyPhen-2, and sorting intolerant from tolerant predictions) were 
identified as potentially causal. Phenotype data from the time of diagnosis were 
also captured.
RESULTS: Eight hundred sixty-four patients with idiopathic or heritable PAH and 
16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis 
were recruited. Mutations in BMPR2 were identified in 130 patients (14.8%). 
Biallelic mutations in EIF2AK4 were identified in 5 patients with a clinical diagnosis 
of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. 
Furthermore, 9 patients with a clinical diagnosis of PAH carried biallelic EIF2AK4 
mutations. These patients had a reduced transfer coefficient for carbon monoxide 
(Kco; 33% [interquartile range, 30%–35%] predicted) and younger age at diagnosis 
(29 years; interquartile range, 23–38 years) and more interlobular septal thickening 
and mediastinal lymphadenopathy on computed tomography of the chest 
compared with patients with PAH without EIF2AK4 mutations. However, radiological 
assessment alone could not accurately identify biallelic EIF2AK4 mutation carriers. 
Patients with PAH with biallelic EIF2AK4 mutations had a shorter survival.
CONCLUSIONS: Biallelic EIF2AK4 mutations are found in patients classified 
clinically as having idiopathic and heritable PAH. These patients cannot be 
identified reliably by computed tomography, but a low Kco and a young age 
at diagnosis suggests the underlying molecular diagnosis. Genetic testing can 
identify these misclassified patients, allowing appropriate management and early 
referral for lung transplantation.
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Pulmonary arterial hypertension (PAH) is a heteroge-neous and rare disorder that can be classified into idiopathic and heritable forms, associated with an 
underlying condition such as connective tissue disease 
or congenital heart disease or related to specific drugs 
and toxins.1,2 In addition, pulmonary veno-occlusive dis-
ease (PVOD) and pulmonary capillary hemangiomatosis 
(PCH) are even rarer forms of pulmonary hypertension 
that are grouped together with PAH under the current 
classification system.2
Clinical features described in patients with PVOD/PCH 
include a low transfer coefficient for carbon monoxide 
(Kco) and oxygen desaturation on exertion, as well as 
the presence of centrilobular ground glass opacification, 
interlobular septal thickening, and mediastinal lymph-
adenopathy on high-resolution computed tomography 
(CT) of the lung parenchyma.3,4 However, these clinical 
and radiological features have also been reported in 
idiopathic PAH.5–7 Consequently, the clinical distinction 
between PVOD/PCH and idiopathic PAH can be chal-
lenging. It has been estimated that 10% of patients 
with PVOD/PCH are misdiagnosed as having idiopathic 
PAH.8,9 The diagnosis of PVOD/PCH is often confirmed 
only postmortem or from explanted lungs by histology.
The histological features of PVOD/PCH typically in-
clude pulmonary venous obstructions and pulmonary 
capillary proliferation, although the distribution of these 
changes within the lung can be heterogeneous.10,11 Pul-
monary artery smooth muscle hypertrophy and intimal 
hyperplasia, similar to the changes observed in other 
forms of PAH, may also be present. Furthermore, pulmo-
nary venous changes have been reported in cases of id-
iopathic PAH, patients with scleroderma-associated PAH, 
and those with BMPR2 mutations to varying extents.12,13
A major advance in the molecular diagnosis of 
PVOD/PCH was the finding of biallelic mutations in the 
gene encoding the eukaryotic translation initiation fac-
tor 2 alpha kinase 4 (EIF2AK4) in both familial (100%) 
and sporadic (20% to 25%) cases of PVOD/PCH.14,15 EI-
F2AK4 is an activator of the integrated stress response 
pathway and responds to environmental stresses, in-
cluding amino acid deprivation, by phosphorylating 
the α subunit of eukaryotic translation initiation factor 
2.11,16,17 These discoveries suggest that EIF2AK4 muta-
tions are specific to PVOD/PCH and that finding biallelic 
EIF2AK4 mutations in a patient with pulmonary hyper-
tension would be diagnostic of PVOD/PCH. Patients 
with PVOD/PCH have a poor prognosis and risk fatal 
pulmonary edema with the use of pulmonary artery 
vasodilator therapies.4,18–20 Consequently, early and ac-
curate diagnosis is vital to guide clinical management.
Heterozygous mutations in the gene encoding the 
bone morphogenetic protein type 2 receptor (BMPR2) are 
the most common genetic cause of PAH. They are found 
in ≈17% of individuals with idiopathic PAH and 82% with 
a family history of the disease.21 However, mutations in 
BMPR2 have also been reported in patients with histologi-
cally proven PVOD.4,22–24 Thus, considerable uncertainty re-
mains as to what extent the finding of EIF2AK4 or BMPR2 
mutations reliably predicts the clinical phenotype and re-
sponse to therapy in a population of patients with PAH.
Here, we report the genetic and phenotypic charac-
teristics of patients assessed for BMPR2 and EIF2AK4 
mutations through whole-genome sequencing within a 
large cohort (n=880) of patients with PAH recruited to 
the National Institute of Health Research (NIHR) BRIDGE 
study (BioResource–Rare Diseases) (Table I in the online-
only Data Supplement). The frequency of mutations in 
other previously reported genes associated with PAH 
will be reported in a future publication. In this study, 
we identified and characterized patients with a clinical 
Clinical Perspective
What Is New?
• One percent of patients with a clinical diagnosis of 
pulmonary arterial hypertension (PAH) carry bial-
lelic EIF2AK4 mutations.
• Patients diagnosed clinically with PAH who had a 
transfer coefficient for carbon monoxide (Kco) <50% 
predicted and age of diagnosis <50 years were more 
likely to carry biallelic EIF2AK4 mutations. The diag-
nostic yield for genetic testing in this group was 53%.
• Radiological assessment was unable to distinguish 
reliably between these patients and patients with 
idiopathic PAH.
• Histology from these patients may show predomi-
nately pulmonary arteriopathy, with subtle involve-
ment of the pulmonary veins and capillaries.
• Patients with PAH with biallelic EIF2AK4 muta-
tions had a worse prognosis compared with other 
patients with PAH.
What Are the Clinical Implications?
• Younger patients diagnosed with idiopathic PAH 
but with a low Kco have a high frequency of bial-
lelic EIF2AK4 mutations.
• Such patients should be reclassified as having pul-
monary veno-occlusive disease/pulmonary capillary 
hemangiomatosis.
• Similar to patients with pulmonary veno-occlusive 
disease/pulmonary capillary hemangiomatosis, 
these patients have a poor prognosis compared 
with other patients with PAH.
• The spectrum of radiological and histological 
changes associated with biallelic EIF2AK4 mutations 
is wider than previously assumed. The presence of 
only subtle or infrequent features associated with 
pulmonary veno-occlusive disease may lead to mis-
classification of these patients as having PAH.
• Genetic testing allows early identification of these 
patients, facilitating appropriate management.
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and radiological diagnosis of idiopathic PAH who were 
found to possess biallelic EIF2AK4 mutations. These pa-
tients had a low Kco and were diagnosed at a younger 
age compared with patients with idiopathic PAH with-
out mutations in these genes. We show that, in com-
mon with patients diagnosed clinically with PVOD/PCH, 
patients with PAH with biallelic EIF2AK4 mutations 
have a shorter survival. We conclude that clinical assess-
ment alone is inadequate for the accurate diagnosis of 
PVOD/PCH. Clinical genetic testing in younger patients 
presenting clinically with PAH but with a low Kco will 
allow appropriate classification, leading to better risk 
stratification and management of these patients.
METHODS
Ethics Approval and Consent
UK patients (621 [70.6%]) were recruited prospectively to 
the BRIDGE study and provided written informed consent 
for genetic analysis and the capture of clinical data (BRIDGE 
study 13/EE/0325). In addition, the study included patients 
recruited retrospectively from non-UK centers (191 [21.7%]) 
and deceased UK patients (68 [7.7%]) if they had signed local 
tissue bank consent forms allowing genetic sequencing.
Explanted lung tissue from an individual undergoing 
lung transplantation for end-stage PAH was collected under 
Papworth Hospital Research Tissue Bank ethics (08/H0304/56).
Recruitment and Patients
The BRIDGE study is a prospective study recruiting both 
prevalent and incident patients with selected rare diseases. 
Recruitment to the BRIDGE PAH study started in January 2013, 
and the last patient included in this analysis was recruited 
on June 15, 2016. Patients with idiopathic PAH, heritable 
PAH, PVOD, and PCH, diagnosed according to international 
guidelines at specialist pulmonary hypertension centers in the 
United Kingdom, the Netherlands, and France, were recruited 
(Figure 1 and Table II in the online-only Data Supplement).2 
This included 14 patients with confirmed mutations in BMPR2.
Throughout this article, we classify patients recruited to 
the study as having idiopathic PAH or familial PAH on the 
basis of the absence or presence of a family history of the 
disease. The term heritable PAH does not distinguish between 
patients with sporadic PAH with a mutation and patients with 
a mutation who have a family history. Therefore, the term 
heritable PAH is used only when referring to previous publica-
tions and guidelines.
Patients with other rare diseases and their unaffected rela-
tives recruited to the BRIDGE study (Table III in the online-only 
Data Supplement) acted as control subjects without PAH for 
the genetic analysis.
Whole-Genome Sequencing  
and Variant Calling
Next-generation sequencing with 100– to 150–base pair (bp) 
paired-end sequencing was performed on DNA libraries cre-
ated from genomic DNA with Illumina HiSeq 2500 and HiSeq 
X (Illumina Inc, San Diego, CA).
Reads were aligned against the Genome Reference 
Consortium human genome (build 37), and variants were 
called with the Isaac Aligner and Variant Caller (version 2, 
Illumina Inc). Variants in BMPR2 and EIF2AK4 were extracted 
and annotated with the Ensembl Variant Effect Predictor ver-
sion 84.25 Deletions (resulting in the loss of >50 bp) were 
identified by applying Isaac Copy Number Variant Caller 
(Canvas, Illumina) and Isaac Structural Variant Caller (Manta, 
Illumina). Further information is provided in the online-only 
Data Supplement.
Likely causal variants were identified on the basis of minor 
allele frequency and predicted deleteriousness. Variants were 
considered further if they had a minor allele frequency of <1 
in 10 000 in unrelated BRIDGE control subjects without PAH 
and the ExAC database.26 The rare variants that passed the 
minor allele frequency filtering were then assessed for delete-
riousness. Variants were considered pathogenic on the basis 
of a combined annotation-dependent depletion score of ≥15 
and PolyPhen-2 or sorting intolerant from tolerant predictions 
not classified as benign or tolerated, respectively.27–29
Overrepresentation Analyses
For comparison of variant frequencies between disease and 
control groups, only variants from unrelated individuals were 
used. The PRIMUS software package was used to identify 
Figure 1. Subjects recruited to 
the National Institute of Health 
Research (NIHR) BRIDGE study 
(BioResource–Rare Diseases) and 
the clinical diagnostic categories 
of patients with pulmonary arte-
rial hypertension (PAH) included 
in this study.  
PVOD/PCH indicates pulmonary veno-
occlusive disease/pulmonary capillary 
hemangiomatosis.
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nonrelated individuals among both BRIDGE control subjects 
without PAH and patients with PAH.30 The number of unre-
lated control subjects was maximized by including either 
patients with other rare diseases or their unaffected relatives. 
The frequency of rare and predicted deleterious heterozygous 
EIF2AK4 variants in PAH index cases was also compared with 
publically available information in the ExAC database (http://
exac.broadinstitute.org).26 This analysis provides the maxi-
mum estimate of the frequency of heterozygous EIF2AK4 
variants in the ExAC database because variants in ExAC were 
assumed not to be in a compound heterozygous state.
Phenotypic Data Capture and CT 
Assessment
Paper and electronic patient records of patients with PAH 
were reviewed to capture demographic and phenotypic 
variables from the time of diagnosis and follow-up. Survival 
data for UK patients were obtained from recruiting cen-
ters through the NHS National Spine and local databases. 
Anonymized information was captured securely online with 
the free OpenClinica software, adapted for data capture spe-
cific to PAH.
CT images of the chest, when available, were reviewed 
independently by 2 cardiothoracic radiologists (A.S. and N.S.) 
with specialist imaging experience in pulmonary hyperten-
sion who were blinded to the underlying diagnoses with a 
customized proforma. Further information is provided in the 
supplemental materials and Tables IV and V in the online-only 
Data Supplement.
Statistical Analysis
Statistical analysis was performed in R (www.r-project.org). 
Further information is provided in the online-only Data 
Supplement.
Semiparametric Cox proportional hazard models were 
used to assess survival between groups with the survival pack-
age in R. Time from diagnosis to both death and death or 
transplantation was assessed. Age at diagnosis and sex were 
used as covariates in the models. To avoid immortal time bias 
arising from the inclusion of retrospectively recruited patients 
and prevalent patients, a sensitivity analysis was conducted. 
In this analysis, only prospectively recruited patients from the 
UK were included, and patients entered the risk set only from 
the time they consented to the study. Further information is 
provided in the online-only Data Supplement.
RESULTS
Study Patients
Whole-genome sequencing was performed on 932 
patients recruited to the NIHR BRIDGE PAH study and 
7134 control subjects without PAH recruited to other 
NIHR BRIDGE study cohorts. Fifty-two patients were ex-
cluded from further analysis because they did not have 
a clinical diagnosis of idiopathic PAH, heritable PAH, 
PVOD, or PCH (Figure 1). The remaining 880 patients 
(of whom 872 were defined as unrelated index cases) 
consisted of 16 patients (1.8%) with a clinical diagnosis 
of PVOD/PCH, 56 (6.4%) with PAH and a family his-
tory of the disease (referred to as familial PAH), and 808 
(91.8%) with idiopathic PAH and no known family his-
tory. One of the 16 patients with a clinical diagnosis of 
PVOD/PCH had an affected sister, whereas the remain-
der had the sporadic form of the disease.
BMPR2 Mutations in the PAH Cohort
Rare and predicted deleterious BMPR2 mutations 
(single-nucleotide variants, indels, and larger dele-
tions) were found in 41 patients (73.2%) with familial 
PAH and 89 patients (11.0%) with idiopathic PAH. No 
BMPR2 mutations were found in patients with a clinical 
diagnosis of PVOD/PCH.
Rare and Predicted Deleterious EIF2AK4 
Variants in the PAH Cohort
Sixty-nine rare and predicted deleterious EIF2AK4 sin-
gle-nucleotide variants and indels were present in the 
NIHR BRIDGE study. No large deletions were found that 
affected the EIF2AK4 gene locus. The variants are sum-
marized in Table VI in the online-only Data Supplement. 
Five of the 16 patients (31.3%) with clinically diag-
nosed PVOD/PCH carried biallelic EIF2AK4 mutations (2 
homozygotes and 3 compound heterozygotes).
Twenty-five EIF2AK4 variants were also found in 19 
patients (2.2%) diagnosed clinically with PAH, in whom 
there was no clinical suspicion of PVOD/PCH (5 homo-
zygotes, 4 compound heterozygotes, and 10 heterozy-
gotes; Table VII in the online-only Data Supplement). 
One of these patients with a homozygous EIF2AK4 mu-
tation (c.3097C>T creating a premature stop codon) 
had a sister who had died of PAH. There was no re-
ported family history of PVOD/PCH.
The remaining rare EIF2AK4 variants were found in a 
heterozygous state in 36 control subjects (0.5%). Four 
of these variants appeared in >1 control subject with-
out PAH, and none were shared with patients with PAH.
Overrepresentation of Rare 
Heterozygous EIF2AK4 Variants in 
Patients With Idiopathic PAH Compared 
With Control Subjects
The proportion of patients with a clinical diagnosis of 
idiopathic PAH carrying heterozygous rare EIF2AK4 
variants (1.2%) was significantly greater than the 
percentage of control subjects without PAH (0.5%; 
P=0.030). A similar overrepresentation in patients with 
idiopathic PAH was observed compared with allele fre-
quencies in the ExAC database (0.6%; P=0.042). Two 
patients with idiopathic PAH with heterozygous rare 
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EIF2AK4 variants also carried a rare and predicted del-
eterious BMPR2 mutation.
Phenotype of Patients With a Clinical 
Diagnosis of PAH and Biallelic EIF2AK4 
Mutations
Patients with a clinical diagnosis of PAH and biallelic EI-
F2AK4 mutations presented at a younger age (median, 
29 years; interquartile range, 23–38 years) compared 
with patients without mutations in the PAH associated 
genes (51 years; IQR, 37–65 years; P=0.024; Table 1). 
Mean pulmonary artery pressure, cardiac output, and 
pulmonary vascular resistance were not significantly dif-
ferent between patients with PAH with biallelic EIF2AK4 
mutations and the other groups. As previously report-
ed, hemodynamic variables were significantly worse in 
patients with BMPR2 mutations compared with those 
without any mutations in these genes.
The patients with PAH with biallelic EIF2AK4 muta-
tions exhibited a reduced Kco (33% [IQR, 30%–35%] 
predicted) compared with BMPR2 mutation carriers 
(81% [IQR, 73%–92%] predicted; P<0.001) and pa-
tients with PAH with no identified mutation (71% [IQR, 
51%–85%] predicted; P=0.001). Patients with PAH 
with biallelic EIF2AK4 mutations had no obstructive or 
restrictive deficit on spirometry. These differences re-
mained after the exclusion of patients with abnormal 
spirometry in the other groups (forced expiratory vol-
ume in 1 second of expiration [FEV1] <80% or forced 
vital capacity [FVC] <80%; Table VIII in the online-only 
Data Supplement).
Digital clubbing was overrepresented among pa-
tients with biallelic EIF2AK4 mutations diagnosed clini-
cally with PAH (42%; P=0.002). Eleven percent of pa-
tients with a clinical diagnosis of PVOD were clubbed.
Only 1 patient with a heterozygous rare and pre-
dicted deleterious EIF2AK4 variant (c.2516T>C) had a 
reduced Kco (54% predicted) with normal spirometry 
(FEV1, 102% predicted; FVC, 98% predicted; and total 
lung capacity, 100% predicted). There was mild para-
septal emphysema on thoracic CT (<5% of the lung 
parenchyma affected). This patient, a 44-year-old white 
man diagnosed with idiopathic PAH, also carried a 
rare and deleterious BMPR2 splice acceptor mutation 
(c.853-2A>G).
We questioned whether Kco was a predictor of bial-
lelic EIF2AK4 mutations in the wider cohort. However, 
among patients with PAH with no mutations and nor-
mal spirometry (n=255), a reduced Kco (<50% pre-
dicted) was present in 65 patients (25.5%). In these 
patients with a reduced Kco and preserved spirometry, 
90.8% were >50 years old at diagnosis, and 69.2% 
had a history of coronary artery disease, left ventricu-
lar dysfunction, or cardiovascular risk factors (diabetes 
mellitus, systemic hypertension, or hyperlipidemia).
Table 1. Phenotypic Summary of EIF2AK4 Variant Carriers: Patients With a Clinical Diagnosis of PAH and Biallelic 
EIF2AK4 Mutations Were Younger at Diagnosis and Had a Significantly Reduced Kco Compared With Other Groups
 
PAH Patients 
With BMPR2 
Mutations*
PAH Patients With 
No Mutations in PAH-
Associated Genes
PAH Patients With 
EIF2AK4 Heterozygous 
Variants
PAH Patients With 
Biallelic EIF2AK4 
Mutations
Patients With 
PVOD/PCH P Value
n 130 704 8 9 16  
Age, y 39 (31–52) 51 (37–65) 49 (36–67) 29 (23–38) 57 (41–69) <0.001
Female, n (%) 85 (65.4) 494 (70.2) 7 (87.5) 4 (44.4) 9 (56.2) 0.180
White, n (%) 108 (83.1) 551 (78.5) 5 (62.5) 2 (22.2) 13 (81.2) 0.002
Digital clubbing, n (%) 6 (9.7) 10 (3.4) 0 (0) 3 (42.9) 1 (11.1) 0.002
BMI, kg/m2 28 (24–33) 28 (24–33) 26 (23–28) 24 (20–27) 27 (24–31) 0.216
mPAP, mm Hg 57 (51–69) 52 (44–61) 44 (42–52) 52 (46–65) 48 (40–58) <0.001
CO, L/min 3 (3–4) 4 (3–5) 3 (3–5) 5 (3–6) 4 (3–4) <0.001
PVR, WU 15 (11–20) 10 (7–14) 9 (6–10) 9 (8–13) 10 (9–12) <0.001
Vasoresponders, n (%) 0 (0) 28 (17.5) 0 (0) 0 (0) 0 (0) 0.011
FEV1, % predicted 90 (78–99) 84 (72–95) 83 (71–94) 94 (85–100) 85 (70–95) 0.031
FVC, % predicted 97 (86–109) 95 (82–106) 96 (75–98) 100 (86–119) 97 (81–103) 0.310
KCO, % predicted 81 (73–92) 71 (51–85) 81 (72–95) 33 (30–35) 37 (32–47) <0.001
Resting SAo2, % 96 (94–97) 96 (93–97) 98 (98–98) 91 (90–94) 94 (91–95) 0.010
SAo2 after walk test, % 94 (90–97) 92 (85–96) 94 (84–96) 78 (75–82) 88 (85–89) <0.001
BMI indicates body mass index; CO, cardiac output; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; Kco, transfer coefficient for carbon 
monoxide; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PCH, pulmonary capillary hemangiomatosis; PVOD, pulmonary veno-
occlusive disease; PVR, pulmonary vascular resistance; and SAo2, arterial oxygen saturation. 
*Also includes the 2 patients with a heterozygous EIF2AK4 variant and a BMPR2 variant. Data presented as median (interquartile range) unless indicated. 
Percentages were calculated from the number of patients for whom data were available as the denominator.
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Given the high prevalence of a low Kco with pre-
served spirometry in the wider cohort, we restricted an 
analysis to patients <50 years of age who at the time of 
diagnosis had normal spirometry (n=164). Even in this 
group, a significant proportion (n=15, 9.1%) had a Kco 
<50% predicted (Figure 2). Eight of these 15 patients 
carried biallelic EIF2AK4 mutations. One patient with 
biallelic EIF2AK4 mutations was 70 years of age at diag-
nosis and subsequently did not meet this cutoff.
Among patients with normal spirometry, the pres-
ence of a Kco <50% predicted and age at diagnosis 
<50 years had a high sensitivity (0.889) and specificity 
(0.977) for identifying patients who carry biallelic EI-
F2AK4 mutations; the positive predictive value was low 
(0.533). Nevertheless, in terms of the diagnostic yield, 
although genetic testing for biallelic EIF2AK4 mutations 
in the entire cohort of patients diagnosed clinically with 
PAH yielded a 1% detection rate, the presence of bial-
lelic EIF2AK4 mutations in patients with PAH with a Kco 
<50% predicted with normal spirometry and <50 years 
of age at diagnosis was 53%.
CT Features of EIF2AK4 Mutation Carriers
Centrilobular ground glass opacification extent, medi-
astinal lymphadenopathy, and interlobular septal thick-
ening are considered suggestive of PVOD/PCH. Howev-
er, we found subtle or gross centrilobular ground glass 
opacification in 38% of patients diagnosed clinically 
with PAH and carrying no mutations (n=21) and 67% of 
patients with PAH with BMPR2 mutations (n=21). This 
was not significantly different compared with patients 
with a clinical diagnosis of PAH and biallelic EIF2AK4 
mutations (86%, n=7) and patients with a clinical diag-
nosis of PVOD (50%, n=14). Gross interlobular septal 
thickening and mediastinal lymphadenopathy were sig-
nificantly more frequent among patients with PAH and 
biallelic EIF2AK4 mutations (29% and 57%, respective-
ly) and those with PVOD (64% and 79%) compared 
with patients with PAH and no mutation (5% and 0%) 
or BMPR2 mutations (5% and 10%). A radiological sus-
picion of PVOD/PCH was raised in 71% of those with 
PVOD, 57% of patients with a clinical diagnosis of PAH 
and biallelic EIF2AK4 mutations, 14% of patients with 
PAH with no mutation, and 5% of those with BMPR2 
mutations (Table 2).
A further CT analysis comparing patients with bi-
allelic EIF2AK4 mutations (with a clinical diagnosis of 
PVOD/PCH or PAH; n=11) and those with a clinical diag-
nosis of PVOD but not carrying biallelic EIF2AK4 muta-
tions (n=10) was made (Table IX in the online-only Data 
Supplement). Patients with biallelic EIF2AK4 mutations 
were younger at diagnosis (27 years; IQR, 23–34 years) 
compared with those with PVOD and no EIF2AK4 mu-
tations (68 years; IQR, 64–72 years; P=0.001). The pa-
tients with biallelic EIF2AK4 mutations also had a lower 
Kco (32% [IQR, 29%–33%] predicted) compared with 
patients with PVOD and no EIF2AK4 mutations (41.4% 
[IQR, 37%–54%] predicted; P=0.013). Centrilobular 
ground glass opacification appeared more extensive 
in those with biallelic EIF2AK4 mutations (82%) com-
pared with those without a mutation (10%; P=0.012). 
However, pleural effusions were more common among 
those without a mutation (40%) compared with pa-
tients with biallelic EIF2AK4 mutations (0%; P=0.035). 
This may suggest that patients with biallelic EIF2AK4 
mutations have a distinct radiological phenotype com-
pared with patients with PVOD and no biallelic EIF2AK4 
mutations.
Response to Pulmonary Artery 
Vasodilator Therapies
The response to pulmonary artery vasodilator therapies 
at 1 and 3 years was assessed for patients with a clini-
cal diagnosis of PAH and biallelic EIF2AK4 mutations 
and the other patients with PAH included in the CT 
analysis. Patients with a clinical diagnosis of PAH and 
biallelic EIF2AK4 mutations did not improve their func-
tional class at either 1 or 3 years after diagnosis, unlike 
the other PAH groups (Table X in the online-only Data 
Supplement).
Histological Features of a Biallelic 
EIF2AK4 Mutation Carrier
The explanted lungs of 1 patient diagnosed with idio-
pathic PAH but found to have a homozygous EIF2AK4 
missense mutation (c.1795G>C, p.G599R) were as-
Figure 2. The transfer coefficient for carbon monoxide 
(Kco) is influenced by genotype in pulmonary arterial 
hypertension (PAH).  
Patients with forced expiratory volume in 1 second of expira-
tion <80% predicted and forced vital capacity <80% pre-
dicted and diagnosed with PAH or pulmonary veno-occlusive 
disease (PVOD)/pulmonary capillary hemangiomatosis after 
50 years of age were excluded from the plot.
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sessed. The predominant histological feature was pul-
monary arterial vasculopathy. The pulmonary arteries 
predominantly showed concentric and eccentric intimal 
fibrosis. No plexiform lesions were observed. Although 
infrequent, there was some fibrosis of the septal veins 
and venules, some of which were nearly completely oc-
cluded. Although there was evidence of capillary con-
gestion, no capillary hemangiomatosis was observed 
(Figure 3). The missense variant carried by this patient 
was not reported in the ExAC database, occurs in a con-
served area of the genome (Genomic Evolutionary Rate 
Profiling score, 5.5), and was predicted to be deleteri-
ous (combined annotation-dependent depletion score, 
32; PolyPhen-2 prediction of “probably damaging [1],” 
sorting intolerant from tolerant prediction of “delete-
rious [0]”). The same homozygous mutation was also 
found in a second unrelated patient with a clinical diag-
nosis of idiopathic PAH.
Impact of Genotype on Survival
Eight hundred fifty-eight patients were included in the 
Cox proportional hazards model (Table XI and Figure 
I in the online-only Data Supplement). Patients diag-
nosed clinically as having PAH with biallelic EIF2AK4 
mutations had a shorter survival time from diagnosis 
compared with the BMPR2 mutation carriers (P<0.001) 
and those without any variants in PAH-associated genes 
(P<0.001). Age (P<0.001) and sex (P=0.001) also had a 
significant effect on survival, with male sex and older 
age at diagnosis associated with shorter survival in the 
model. Similar results were obtained in the assessment 
of time to death or transplantation (Table XII in the on-
line-only Data Supplement). In the sensitivity analysis, 
including only prospectively recruited UK patients, only 
2 events occurred in the biallelic EIF2AK4 group. Thus, 
no significant difference was observed in mortality be-
tween patients diagnosed clinically as having PAH with 
biallelic EIF2AK4 mutations and patients with BMPR2 
mutations (P=0.215) or patients without any variants in 
PAH-associated genes (P=0.282; Table XIII in the online-
only Data Supplement).
DISCUSSION
This is the first study to analyze the frequency of EI-
F2AK4 rare variation in a large cohort of patients with 
PAH and to make detailed phenotypic and radiologi-
cal assessments. Previously, the presence of biallelic EI-
F2AK4 mutations was reported in patients with a clear 
Table 2. Radiological Features and Consensus Radiological Diagnosis of Patients With PAH in the CT Substudy
 Group
Patients With 
PAH With BMPR2 
Mutations (n=21), 
n (%)
Patients With PAH With 
No Mutations in the 
Previously Reported PAH 
Genes (n=21), n (%)
Patients With PAH 
With Heterozygous 
EIF2AK4 Variants 
(n=4), n (%)
Patients With 
PAH With Biallelic 
EIF2AK4 Mutations 
(n=7), n (%)
Patients 
With PVOD 
(n=14), n (%) P Value
Centrilobular 
ground glass 
opacification 
density
None 7 (33.3) 13 (61.9) 2 (50.0) 1 (14.3) 7 (50.0)
0.122Subtle 12 (57.1) 5 (23.8) 0 (0.0) 2 (28.6) 3 (21.4)
Present 2 (9.5) 3 (14.3) 2 (50.0) 4 (57.1) 4 (28.6)
Centrilobular 
ground glass 
opacification 
extent
None 8 (38.1) 13 (61.9) 2 (50.0) 1 (14.3) 8 (57.1)
0.077
<5% 0 (0.0) 3 (14.3) 0 (0.0) 1 (14.3) 1 (7.1)
5%–25% 2 (9.5) 0 (0.0) 1 (25.0) 2 (28.6) 1 (7.1)
25%–50% 2 (9.5) 4 (19.0) 0 (0.0) 0 (0.0) 2 (14.3)
50%–75% 5 (23.8) 1 (4.8) 0 (0.0) 2 (28.6) 0 (0.0)
75%–100% 4 (19.0) 0 (0.0) 1 (25.0) 1 (14.3) 2 (14.3)
Interlobular septal 
thickening
None 17 (81.0) 18 (85.7) 4 (100.0) 5 (71.4) 4 (28.6)
0.001Subtle 3 (14.3) 2 (9.5) 0 (0.0) 0 (0.0) 1 (7.1)
Present 1 (4.8) 1 (4.8) 0 (0.0) 2 (28.6) 9 (64.3)
Mediastinal 
lymphadenopathy
None 19 (90.5) 21 (100.0) 4 (100.0) 3 (42.9) 3 (21.4)
<0.001
Present 2 (9.5) 0 (0.0) 0 (0.0) 4 (57.1) 11 (78.6)
Pleural effusion None 17 (81.0) 21 (100.0) 3 (75.0) 7 (100.0) 10 (71.4)
0.048
Small 4 (19.0) 0 (0.0) 1 (25.0) 0 (0.0) 4 (28.6)
Neovascularity None 12 (57.1) 18 (85.7) 4 (100.0) 6 (85.7) 13 (92.9)
0.077
Present 9 (42.9) 3 (14.3) 0 (0.0) 1 (14.3) 1 (7.1)
CT diagnosis PAH 20 (95.2) 18 (85.7) 3 (75.0) 3 (42.9) 4 (28.6)
 Possible 
PVOD/PCH
1 (4.8) 3 (14.3) 1 (25.0) 4 (57.1) 10 (71.4)
CT indicates computed tomography; PAH, pulmonary arterial hypertension; and PVOD, pulmonary veno-occlusive disease. 
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clinical diagnosis of PVOD/PCH and a large kindred and 
a single family with a possible diagnosis of PAH.20,31,32 
As expected, we identified a high frequency of bial-
lelic EIF2AK4 mutations in patients with a clear clinical 
presentation of PVOD/PCH. However, we also found 
biallelic EIF2AK4 mutations in patients with a clinical 
diagnosis of PAH.
The discovery of biallelic EIF2AK4 mutations in PVOD/
PCH raised the possibility of rapid molecular diagnosis 
in the majority of patients with familial and up to 25% 
of patients with sporadic PVOD/PCH.14,15 In the pres-
ent study, the presence of biallelic EIF2AK4 mutations 
was associated with a poor prognosis, even in patients 
who have a clinical diagnosis of PAH and who did not 
develop pulmonary edema in response to pulmonary 
artery vasodilator therapies. Therefore, early identifi-
cation of these patients through genetic testing may 
prompt early referral for lung transplantation similar to 
patients with clinically diagnosed PVOD/PCH.18
The presence of biallelic EIF2AK4 mutations in pa-
tients with a clinical diagnosis of PAH raises the ques-
tion whether EIF2AK4 mutations can cause classic 
idiopathic PAH or whether there are cases of PVOD/
PCH caused by EIF2AK4 mutations that are wrongly 
classified even by expert centers. We further show that 
phenotypic, radiological, and histological assessments 
can be difficult to interpret. The presence of subtle or 
infrequent features may lead to an incorrect diagnosis 
of PAH in patients with biallelic EIF2AK4 mutations. This 
study suggests that patients with pathogenic biallelic 
Figure 3. Representative histopathologic images from 1 patient with clinically diagnosed idiopathic pulmonary ar-
terial hypertension (PAH) but found to have a rare (not reported in the ExAC database) and predicted deleterious 
(combined annotation-dependent depletion score, 32) homozygous EIF2AK4 missense variant (c.1795G>C).  
The patient was of Pakistani origin and did not have a family history of PAH or pulmonary veno-occlusive disease (PVOD). At 
presentation, he was 22 years old and had a reduced transfer coefficient for carbon monoxide (Kco; 31% predicted) despite 
preserved spirometry. High-resolution computed tomography of his chest showed subtle but extensive (50%–75% involve-
ment) ground glass opacification. No interlobular septal thickening or mediastinal lymphadenopathy was observed. No 
suspicion of PVOD/pulmonary capillary hemangiomatosis (PCH) was raised from the radiological appearances. Histopathology 
was reviewed by 2 independent pathologists, each confirming the predominant histological pattern to be one of pulmonary 
arterial vasculopathy. The pulmonary arteries showed eccentric and concentric intimal fibrosis and medial hypertrophy (A and 
B), as well as some lesions with features of recanalized thrombus (C). Several concentrically muscularized arterioles were also 
observed (D). No complex plexiform lesions were present. There was patchy thickening of the alveolar septa with capillary 
congestion and pigmented intra-alveolar macrophages similar to PCH (E and F). Venous remodeling was difficult to trace and 
infrequent but present. Fibrous thickening of the intima in septal veins (G and I) and a microvessel (H).
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EIF2AK4 mutations may present with a spectrum of 
phenotypic, radiological, and histological features that 
can overlap with PAH.
Patients with PAH with biallelic EIF2AK4 mutations 
demonstrated a reduced Kco despite normal spirom-
etry, which is characteristic of patients with PVOD/PCH. 
The reduced Kco likely reflects widespread reduction in 
alveolar gas exchange caused by endothelial prolifera-
tion and patchy thickening of the blood-gas barrier by 
the process of capillary hemangiomatosis. Ultrastruc-
tural thickening of the capillary basement membrane 
may also play a role.33 In keeping with previous reports 
in PVOD/PCH, we also show that patients with PAH 
with biallelic mutations in EIF2AK4 are younger at di-
agnosis than patients with either BMPR2 mutations 
or no known mutation.14,20 However, the presence of 
these characteristic features has a low positive predic-
tive value for the identification of patients with biallelic 
EIF2AK4 mutations.
In contrast to previous descriptions of patients with 
PVOD, none of the patients with clinically diagnosed 
PAH and biallelic EIF2AK4 mutations developed pulmo-
nary edema in response to pulmonary artery vasodilator 
therapies. For example, intravenous prostanoids were 
used in 50% of these patients. In patients with classic 
PVOD, pulmonary edema with intravenous prostanoids 
has been reported in up to 44% of patients after a me-
dian treatment duration of just 9 days.4 Presumably, the 
extent and severity of the pulmonary venous involve-
ment in these patients might underlie the differing re-
sponses to prostanoids.
It is generally considered that high-resolution CT im-
aging is a useful noninvasive test to assist in the diag-
nosis of suspected PVOD/PCH.11 Although there was an 
increased prevalence of mediastinal lymphadenopathy 
and interlobular septal thickening in patients with PAH 
with biallelic EIF2AK4 mutations, we found that radio-
logical features at the time of diagnosis could not ac-
curately determine the underlying genotype.6 The dif-
fering radiological features of all patients with biallelic 
EIF2AK4 mutations compared with patients with PVOD 
without mutations is of interest. This may reflect dif-
ferences between the younger-onset genetic cases of 
PVOD compared with the predominantly older group 
of patients without EIF2AK4 mutations in whom other 
nongenetic factors such as exposure to inorganic sol-
vents may play an important role.34
Histological examination (usually postmortem or 
from explanted lungs) is often considered essential for 
diagnostic confirmation of PVOD/PCH but may be con-
founded by the heterogeneous nature of vascular pa-
thology.35 Surgical biopsy of the lung in patients with 
severe PAH is contraindicated, and a limitation of this 
study is that lung tissue from only 1 patient with bial-
lelic EIF2AK4 mutations was available for analysis. This 
patient had a rare and predicted deleterious homozy-
gous missense mutation in EIF2AK4. The predominant 
feature on assessment of the explanted lung tissue was 
pulmonary arteriopathy, as usually seen in PAH. Al-
though only infrequent, fibrosis of the septal venules 
and the possible presence of siderophages in the al-
veolar space were observed. These features are found 
in patients with PVOD/PCH. This case supports the hy-
pothesis that patients with biallelic EIF2AK4 mutations 
may present with a spectrum of venous and arterial 
involvement.
There are increasing reports of phenotypic, radio-
logical, and histological similarities between PAH and 
PVOD/PCH.6,12,13 Tenorio et al31 reported a homozygous 
missense mutation in EIF2AK4 in a large kindred of Ibe-
rian Romani with apparent heritable PAH. This kindred 
is likely to have PVOD/PCH because these diagnoses 
were not confirmed histologically and PVOD was sus-
pected in half the patients. More recently, Best et al32 
also report 2 sisters with apparent heritable PAH–car-
rying biallelic EIF2AK4 mutations. These patients also 
had a reduced Kco but had not had high-resolution CT 
assessment of their lung parenchyma, which may have 
altered their clinical diagnosis. Taken together, these 
previous reports are compatible with the findings in this 
larger cohort that patients with a clinical presentation 
of idiopathic or heritable PAH may in fact have underly-
ing PVOD/PCH as determined by genetic analysis.
A strength of this study is the centralized report-
ing of radiographic features. However, the data col-
lection was retrospective and incomplete in some 
cases. Assessing rare diseases such as PAH and PVOD/
PCH with a prospective study recruiting incident cases 
would take a prohibitively long time. This is especially 
true for the assessment of survival and response to 
therapy. In this study including prevalent and ret-
rospectively recruited patients, we demonstrated a 
worse prognosis in patients with a clinical diagnosis 
of PAH and biallelic EIF2AK4. However, the inclusion 
of prevalent and retrospectively recruited patients can 
introduce bias such as immortal time bias, when there 
are long periods between diagnosis and enrollment in 
the study. The effect of immortal time bias and other 
confounders such as the inclusion of prevalent and 
incident cases can be difficult to predict. All groups 
are likely to include patients who died before study 
enrollment and thus would not feature in any analy-
sis. When we attempted to eliminate these sources 
of bias in a sensitivity analysis restricted to prospec-
tively recruited patients from the United Kingdom, 
the study did not have sufficient power to show a 
difference in survival between different genotypes. 
Further studies of survival and response to therapy 
are needed to definitively show whether misclassified 
patients with PAH with biallelic EIF2AK4 mutations 
and patients with classic PVOD with these mutations 
have a similarly poor prognosis.
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The genetic architecture of idiopathic and heritable 
PAH remains to be fully elucidated. Ongoing analysis 
of whole-genome sequence data in our cohort is likely 
to reveal novel rare variation underlying this condition. 
Mutations in BMPR2 account for ≈17% of cases of 
idiopathic PAH, and other known PAH genes account 
for ≈1% to 2% of all cases.21,36 In the present study, 
BMPR2 mutations were found in 11% of patients with-
out a family history of PAH. It is worth noting that pa-
tients with the sporadic form of the disease with no 
reported family history represent a higher burden of 
BMPR2 mutations (n=89) compared with those with a 
family history (n=49). This has important implications 
for clinical genetic testing in patients with sporadic and 
familial disease.
In previous studies, mutations in both EIF2AK4 alleles 
are required to cause PVOD and PCH.14,15 In autosomal 
recessive disorders, it is unusual for the heterozygous 
state to manifest the disease phenotype, and hetero-
zygous EIF2AK4 variants thus would not be expected 
to be pathogenic. In this study, we found a significant 
overrepresentation of heterozygous rare and predicted 
deleterious EIF2AK4 variants in patients with PAH com-
pared with control subjects and report 2 patients with 
rare variants in both BMPR2 and EIF2AK4. Recently, the 
possibility that heterozygous EIF2AK4 variants influence 
the penetrance of BMPR2 mutations has been raised in 
a single family with PAH.37 Further studies are required 
to determine whether heterozygous EIF2AK4 variants 
contribute to pathogenesis in PAH.
CONCLUSIONS
We demonstrate that biallelic EIF2AK4 mutations are 
found in patients diagnosed clinically with idiopathic 
and familial PAH. These patients may have subtle fea-
tures suggestive of PVOD/PCH on close inspection and 
are likely to have underlying PVOD/PCH. The spectrum 
of phenotypic, radiological, and histological features 
found in patients with biallelic EIF2AK4 mutations 
made by current clinical assessments is wider and less 
clear-cut than previously recognized. This may lead to 
misclassification of patients as having PAH rather than 
PVOD and hinders accurate risk stratification. Ascertain-
ing the EIF2AK4 mutation status of patients through 
clinical genetic testing provides additional information 
to aid risk stratification and to guide management. In 
a young patient presenting with apparent PAH, the 
presence of a low Kco with normal spirometry strongly 
suggests the presence of underlying biallelic EIF2AK4 
mutations. Patients with an apparent clinical diagnosis 
of PAH and biallelic EIF2AK4 mutations have a worse 
prognosis compared with patients with BMPR2 muta-
tions and those without these mutations. Clinical ge-
netic testing should aid identification of this high-risk 
group and facilitate early referral for lung transplanta-
tion and appropriate management.
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SUPPLEMENTAL MATERIAL: 
Phenotypic characterisation of EIF2AK4 mutation carriers in a large cohort of patients 
diagnosed clinically with pulmonary arterial hypertension 
Hadinnapola et al.  
 
Supplemental Methods: 
Whole genome sequencing 
Genomic DNA was extracted from whole blood samples prior to assessment of concentration 
by Qubit, and quality by gel electrophoresis. After fragmentation of DNA into 200bp 
fragments (Covaris E220, Covaris Inc, Woburn, USA) DNA libraries were created using Tru 
SeqDNA LT Prep kit (Illumina Inc, San Diego, USA). The libraries underwent next generation 
sequencing using 100-150 base pair paired-end sequencing using Illumina HiSeq 2500 and 
HiSeq X (Illumina Inc, San Diego, USA). 
 
Variant calling 
Reads were aligned against the Genome Reference Consortium human genome (build 37) 
(GRCh37) and variants were called using the Issac Aligner and Variant Caller respectively 
(version 2, Illumina Inc.). Genebuilds for BMPR2 and EIF2AK4 genes were based on Ensembl 
v75. Variants from these genes were extracted and annotated using Ensembl’s Variant Effect 
Predictor (VEP) v84 1. VEP was also used to annotate data from the Exome Aggregation 
Consortium’s (ExAC) database 2.  
 
Deletions (resulting in the loss of more than 50bp) were identified by applying Isaac copy 
number variant caller (Canvas, Illumina) and Isaac Structural Variant Caller (Manta, Illumina).  
 2 
To be called by both Canvas and Manta deletions required a reciprocal overlap of ≥ 20%. 
Overlapping deletions represented in the Zarrei dataset with a reciprocal overlap of ≥ 50% 
and deletions with a non-PAH BRIDGE control frequency of more than 1 in 1,000 were 
excluded 3. 
  
Analysis of computed tomographic images of the chest  
CT images of the chest, where available, were reviewed independently by 2 cardiothoracic 
radiologists (AS and NS), with specialist imaging experience in pulmonary hypertension, 
blinded to the underlying diagnoses using a customised proforma (Supplemental Table 4). In 
addition to CT scans of patients with EIF2AK4 mutations or with a clinical diagnosis of PVOD 
in the cohort, CT scans of patients from Papworth Hospital and the Royal Hallamshire Hospital 
with normal spirometry (FEV1 > 80% predicted and FVC > 80% predicted) and either BMPR2 
mutations (n=21) or no variants in the known PAH genes (n=21) were analysed (Supplemental 
Table 5). A consensus read was undertaken for individual CT features and a mutually agreed 
overall radiological diagnosis was recorded. 
 
Histology 
The explanted lung tissue of one patient with a clinical diagnosis of idiopathic PAH and biallelic 
EIF2AK4 mutations was available for further analysis. Four micrometre (µm) tissue sections 
were cut from formalin-fixed paraffin wax embedded blocks from the explanted lung tissue. 
Representative sections from each lobe of both lungs were stained with Elastic-Van Gieson 
and Haemotoxylin and Eosin stains. Two expert histopathologists examined the sections 
independently by light microscopy. 
 
 3 
Statistical analysis 
Statistical analysis was performed in R (www.r-project.org). 
 
Differences between groups of categorical variables were assessed using the Fisher Exact test. 
Where one of the variables was an ordinal the Cochran-Armitage test was applied using the 
chisq_test function from the “coin” package 4. Differences in continuous variables were 
assessed using the Mann–Whitney U test (2 comparator groups) and the Kruskal-Wallis test 
(3 or more comparator groups). Post-hoc pairwise comparisons were performed using Dunn’s 
Test for multiple testing.  
 
Semi-parametric Cox-proportional hazards models were used to assess survival between 
groups using the “survival” package in R 5. Survival time from diagnosis to death and diagnosis 
to death or transplantation was assessed. Patients were censored at the date of 
transplantation for the primary survival analysis. Age at diagnosis and gender were used as 
covariates in the models.  
 
The proportional hazards assumptions were tested by assessing Schoenfeld residuals over log 
time 6. The goodness of fit of the model was assessed by plotting the log of cumulative hazard 
of Cox-Snell residuals against the log of time and confirming the simple regression has 0 
intercept and slope of 1 7. 
 
The inclusion of retrospectively recruited and prevalent patients in a survival analysis 
assessing time from diagnosis to death/transplantation can cause immortal time bias. The 
immortal time is the period between diagnosis and enrolment in the study and so patients 
 4 
had to have survived till this point. Patients with worse prognosis diagnosed at a similar time 
may not have survived long enough to enrol in the study. To further explore this potential 
bias, a sensitivity analysis was performed including only on UK patients recruited 
prospectively to the study. In this multivariate Cox-proportional hazards model, the survival 
period was defined as the time period from date of diagnosis to date of death and patients 
only entered the risk set after enrolment into the study (consent date).  
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Supplemental Tables 
Supplemental Table 1.  NIHR BioResource – Rare Diseases Collaboration.  See spreadsheet. 
 
Centre Principle 
Investigator 
Clinicians and research staff 
Freeman Hospital, Newcastle, 
UK 
Paul A Corris Alan Greenhalgh, Debbie Shipley, 
Margaret Day 
Golden Jubilee National 
Hospital, Glasgow, UK 
Andrew 
Peacock 
Colin Church, Val Irvine, Fiona Kennedy 
Great Ormond Street 
Hospital, London, UK 
Shahin 
Moledina 
Victoria Cookson 
Hammersmith Hospital and 
Imperial College, London, UK 
Martin R 
Wilkins 
Simon Gibbs, John Wharton, Sonia Ali, 
Larahmie Masati, Sharon Meehan, Ivy 
Wanjiku, Shokri Othman 
Papworth Hospital, 
Cambridge, UK 
Joanna Pepke-
Zaba 
Mark Toshner, Gary Polwarth 
Royal Brompton Hospital, 
London, UK 
Stephen J Wort Rosa DaCosta, Natalie Dormand, Alice 
Parker 
Royal Free Hospital, London, 
UK 
Gerry Coghlan Yvonne Tan, Dipa Ghedia 
Royal Hallamshire Hospital, 
Sheffield, UK 
David G Kiely Robin Condliffe, Amanda Creaser-Myers, 
Stephen Roney, Sara Walker 
Royal United Hospitals Bath 
NHS Foundation Trust, Bath, 
UK 
Jay 
Suntharalingam  
Robert MacKenzie Ross, Mark Grover, Ali 
Grove, Jill Peel, Ann Coy 
University of South Paris Marc Humbert David Montani, Florent Soubrier, Barbara 
Girerd, Mélanie Eyries 
VU University Medical Center, 
Amsterdam, Netherlands 
Anton Vonk 
Noordegraaf 
Harm Bogaard, Anna Huis in't Veld, Gwen 
Schotte, Ale Struiksma 
Supplemental Table 2.  Specialist pulmonary hypertension centres participating in the study 
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Recruiting cohorts n 
Genomics England 1965 
Specialist Pathology: Evaluating Exomes in 
Diagnostics 
1356 
Primary Immune Disorders 1299 
Bleeding and Platelet Disorders 1004 
Pulmonary Arterial Hypertension 932 
Multiple Primary Malignant Tumours 376 
Hypertrophic Cardiomyopathy 187 
Cerebral Small Vessel Diseases 183 
Steroid Resistant Nephrotic Syndrome 161 
Intrahepatic Cholestasis of Pregnancy 140 
Stem Cell & Myeloid Disorders 132 
Primary Membranoproliferative Glomerulonephritis 128 
Neuropathic Pain Disorder 114 
Leber Hereditary Optic Neuropathy 59 
Control 15 
Ehlers-Danlos Syndromes 15 
Supplemental Table 3.  NIHR BioResource - Rare Diseases Study 
recruiting cohorts and GEL 
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Parameter Response 
ID  
Date of birth  
Unenhanced CT (Y/N) 
CTPA (Y/N) 
HRCT (Y/N) 
Expiratory CT (Y/N) 
Pulmonary artery diameter (cm)  
Aorta diameter (cm)  
Ground glass opacification centrilobular pattern 
DENSITY 
(None / Subtle / Present) 
Ground glass centrilobular pattern EXTENT (0, <5%, 5-25, 25-50, >50) 
Ground glass DISTRIBUTION 
(central (C)/peripheral (P)/zonal 
(Z) or diffuse (D)) 
Non-specific mosaic pattern / GGO  
Neovascularity vessels (Y/N) 
Arterio-venous malformations (Y/N) 
Bronchial arteries (Y/N) 
Largest bronchial artery size  
Interlobular septal thickening (None, Subtle, Present) 
Mediastinal lymphadenopathy (Y/N) 
Emphysema 
(Y/N) and % of parenchyma 
involved 
Fibrosis 
(Y/N) and % of parenchyma 
involved 
Pleural effusion (Y/N) 
Air trapping (Y/N) 
Comments  
Likely diagnosis 
Any suspicion of PVOD or PCH / 
PAH 
Supplemental Table 4.  Proforma used in analysis of CT scans 
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Group n 
PAH patients with BMPR2 variants 21 
PAH patients with biallelic EIF2AK4 
variants 
7 
PVOD patients 14 
PAH patients with heterozygous EIF2AK4 
variants 
4 
PAH patients with no variants in the 
previously reported PAH genes 
21 
Supplemental Table 5.  CT scans of patients with PVOD and 
patients with PAH carrying biallelic EIF2AK4 mutations were 
reassessed by radiologists blinded to the diagnosis.  For 
comparison CT scans of PAH patients with normal 
spirometry (FEV1 > 80 % predicted and FVC > 80 % 
predicted) who either had no mutations in the previously 
reported PAH genes or carried BMPR2 mutations were 
assessed. 
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Supplemental Table 6.  Page 1/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-2 SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
BRIDGE 
control 
c.292C>G missense 
variant 
p.L98V 0 1 0.00001656 probably 
damaging 
(0.999) 
deleterious 
(0) 
25.7 Heterozygous 
variant 
BRIDGE 
control 
c.354_355delTG frameshift 
variant 
p.C118Wfs*7 0 2 Not found 
in ExAC 
  35 Heterozygous 
variant 
BRIDGE 
control 
c.745C>T stop gained & 
splice region 
variant 
p.R249* 0 1 0.00007451   39 Heterozygous 
variant 
BRIDGE 
control 
c.746G>A missense 
variant & splice 
region variant 
p.R249Q 0 1 2.48E-05 probably 
damaging 
(0.999) 
deleterious 
(0.02) 
34 Heterozygous 
variant 
BRIDGE 
control 
c.767G>T missense 
variant 
p.C256F 0 1 1.66E-05 possibly 
damaging 
(0.904) 
deleterious 
(0.02) 
28.4 Heterozygous 
variant 
BRIDGE 
control 
c.985G>A missense 
variant 
p.E329K 0 1 Not found 
in ExAC 
probably 
damaging 
(0.981) 
deleterious 
(0.01) 
34 Heterozygous 
variant 
BRIDGE 
control 
c.1153dupG frameshift 
variant 
p.V385Gfs*30 0 1 0.00003308   32 Heterozygous 
variant 
BRIDGE 
control 
c.1190T>A missense 
variant 
p.I397N 0 1 Not found 
in ExAC 
possibly 
damaging 
(0.67) 
deleterious 
(0) 
32 Heterozygous 
variant 
Supplemental Table 6.  Summary of rare (MAF < 0.0001) and predicted deleterious (CADD score > 15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 2/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-2 SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
BRIDGE 
control 
c.1215C>G stop gained p.Y405* 0 2 Not found in 
ExAC 
  29.4 Heterozygous 
variant 
BRIDGE 
control 
c.1331A>G missense 
variant 
p.Y444C 0 1 Not found in 
ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
28.7 Heterozygous 
variant 
BRIDGE 
control 
c.1345C>T missense 
variant 
p.R449C 0 1 0.00001654 probably 
damaging 
(1) 
deleterious 
(0) 
35 Heterozygous 
variant 
BRIDGE 
control 
c.2249T>A missense 
variant & splice 
region variant 
p.L750Q 0 1 Not found in 
ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
28 Heterozygous 
variant 
BRIDGE 
control 
c.2298delG frameshift 
variant 
p.N767Tfs*24 0 1 Not found in 
ExAC 
  28.3 Heterozygous 
variant 
BRIDGE 
control 
c.2720A>T missense 
variant 
p.Y907F 0 4 1.66E-05 probably 
damaging 
(1) 
deleterious 
(0) 
31 Heterozygous 
variant 
BRIDGE 
control 
c.2828C>T missense 
variant 
p.T943M 0 1 0.00003311 probably 
damaging 
(1) 
deleterious 
(0) 
34 Heterozygous 
variant 
BRIDGE 
control 
c.3104_3106delT
CT 
inframe 
deletion 
p.F1035del 0 1 Not found in 
ExAC 
  22 Heterozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 3/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
BRIDGE 
control 
c.3217C>T missense 
variant 
p.R1073C 0 1 0.0000166 probably 
damaging 
(1) 
deleterious 
(0) 
35 Heterozygous 
variant 
BRIDGE 
control 
c.3223T>G missense 
variant 
p.F1075V 0 1 0.0000083 probably 
damaging 
(0.997) 
deleterious 
(0) 
32 Heterozygous 
variant 
BRIDGE 
control 
c.3344C>T missense 
variant 
p.P1115L 0 1 8.26E-06 probably 
damaging 
(1) 
deleterious 
(0) 
35 Heterozygous 
variant 
BRIDGE 
control 
c.3358-3C>T splice region 
variant & 
intron variant 
p.NA 0 1 Not found 
in ExAC 
  17.15 Heterozygous 
variant 
BRIDGE 
control 
c.3406C>T stop gained & 
splice region 
variant 
p.R1136* 0 1 Not found 
in ExAC 
  40 Heterozygous 
variant 
BRIDGE 
control 
c.3430A>T missense 
variant 
p.R1144W 0 1 0.0000248 probably 
damaging 
(1) 
deleterious 
(0) 
33 Heterozygous 
variant 
BRIDGE 
control 
c.3986T>C missense 
variant 
p.F1329S 0 1 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
33 Heterozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 4/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
BRIDGE 
control 
c.3992T>C missense 
variant 
p.F1331S 0 1 8.28E-06 possibly 
damaging 
(0.872) 
deleterious 
(0.01) 
28.4 Heterozygous 
variant 
BRIDGE 
control 
c.4039G>A missense 
variant 
p.A1347T 0 1 8.28E-05 probably 
damaging 
(1) 
deleterious 
(0) 
34 Heterozygous 
variant 
BRIDGE 
control 
c.4388_4389+12
delAGGTAAAGAC
GTCA 
splice donor 
variant & 
coding 
sequence 
variant & 
intron variant 
p.NA 0 1 Not found 
in ExAC 
  36 Heterozygous 
variant 
BRIDGE 
control 
c.4397C>A missense 
variant 
p.S1466Y 0 2 Not found 
in ExAC 
probably 
damaging 
(0.988) 
deleterious 
(0) 
33 Heterozygous 
variant 
BRIDGE 
control 
c.4729G>A missense 
variant & splice 
region variant 
p.V1577M 0 1 Not found 
in ExAC 
probably 
damaging 
(0.999) 
deleterious 
(0) 
29.6 Heterozygous 
variant 
BRIDGE 
control 
c.4751dupT frameshift 
variant 
p.L1585Ifs*11 0 1 Not found 
in ExAC 
  34 Heterozygous 
variant 
BRIDGE 
control 
c.4920_4931delT
AGAGATGACTA 
inframe 
deletion 
p.R1641_Y1644
del 
0 1 Not found 
in ExAC 
  23 Heterozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 5/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
PAH c.44C>T missense 
variant 
p.P15L 1 0 8.32E-06 unknown 
(0) 
deleterious 
low 
confidence 
(0.03) 
23.5 Heterozygous 
variant 
PAH c.220G>A missense 
variant 
p.D74N 1 0 1.66E-05 possibly 
damaging 
(0.954) 
deleterious 
(0) 
32 Heterozygous 
variant 
PAH c.1072_1073dup
GT 
frameshift 
variant 
p.V359* 1 0 Not found 
in ExAC 
  32 Heterozygous 
variant 
PAH c.1660G>T missense 
variant & splice 
region variant 
p.D554Y 1 0 Not found 
in ExAC 
probably 
damaging 
(0.966) 
deleterious 
(0) 
28 Heterozygous 
variant 
PAH c.2446C>T stop gained p.Q816* 1 0 Not found 
in ExAC 
  41 Heterozygous 
variant 
PAH c.2516T>C missense 
variant 
p.I839T 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
28.9 Heterozygous 
variant 
PAH c.3218G>T missense 
variant 
p.R1073L 1 0 Not found 
in ExAC 
probably 
damaging 
(0.995) 
deleterious 
(0.01) 
35 Heterozygous 
variant 
PAH c.3604C>T missense 
variant 
p.H1202Y 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
29.7 Heterozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 6/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
PAH c.3711_3713del
GAG 
inframe 
deletion 
p.R1238del 1 0 0.0000083   21.6 Heterozygous 
variant 
PAH c.3722A>G missense 
variant 
p.E1241G 1 0 Not found 
in ExAC 
probably 
damaging 
(0.971) 
deleterious 
(0) 
27.2 Heterozygous 
variant 
PAH c.4646G>A missense 
variant 
p.R1549H 1 0 0.0000910 probably 
damaging 
(0.998) 
deleterious 
(0.01) 
35 Heterozygous 
variant 
PAH c.145-2A>G splice acceptor 
variant 
p.NA 1 0 Not found 
in ExAC 
  23.9 Additional 
second (likely 
trans) variant 
identified 
PAH c.257+4A>C splice region 
variant & 
intron variant 
p.NA 1 0 8.28E-06   15.5 Additional 
second (likely 
trans) variant 
identified 
PAH c.1392delT frameshift 
variant 
p.R465Vfs*38 1 0 2.48E-05   35 Additional 
second (likely 
trans) variant 
identified 
PAH c.1739dupA frameshift 
variant 
p.R581Efs*9 1 0 Not found 
in ExAC 
  35 Additional 
second (likely 
trans) variant 
identified 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 7/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
PAH c.1820T>G missense 
variant & splice 
region variant 
p.V607G 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
27.3 Additional 
second (likely 
trans) variant 
identified 
PAH c.2727C>G missense 
variant 
p.S909R 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
33 Additional 
second (likely 
trans) variant 
identified 
PAH c.2827A>G missense 
variant 
p.T943A 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
26.4 Additional 
second (likely 
trans) variant 
identified 
PAH c.2841delG frameshift 
variant 
p.I948Sfs*35 1 0 Not found 
in ExAC 
  35 Additional 
second (likely 
trans) variant 
identified 
PAH c.3055_3064delC
TGACCAACG 
frameshift 
variant 
p.L1019Wfs*9 1 0 Not found 
in ExAC 
  36 Additional 
second (likely 
trans) variant 
identified 
PAH c.3097C>T stop gained p.Q1033* 3 0 8.24E-06   45 Additional 
second (likely 
trans) variant 
identified 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 8/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
PAH c.3325G>A missense 
variant 
p.G1109R 1 0 0.0000082 probably 
damaging 
(1) 
deleterious 
(0.02) 
35 Additional 
second (likely 
trans) variant 
identified 
PAH c.3884T>G missense 
variant 
p.L1295R 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
32 Additional 
second (likely 
trans) variant 
identified 
PAH c.4400dupT frameshift 
variant 
p.E1468Rfs*14 1 0 Not found 
in ExAC 
  36 Additional 
second (likely 
trans) variant 
identified 
PAH c.4418_4421delC
AGA 
frameshift 
variant 
p.T1473Rfs*17 1 0 0.0000083   36 Additional 
second (likely 
trans) variant 
identified 
PAH c.4769delT frameshift 
variant 
p.L1590* 1 0 0.0000083   33 Additional 
second (likely 
trans) variant 
identified 
PAH c.281dupA frameshift 
variant 
p.N94Lfs*8 2 0 Not found 
in ExAC 
  35 Homozygous 
variant 
PAH c.1159_1160delC
T 
frameshift 
variant 
p.L387Cfs*27 2 0 Not found 
in ExAC 
  29.6 Homozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 9/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
PAH c.1795G>C missense 
variant 
p.G599R 4 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
32 Homozygous 
variant 
PAH c.3097C>T stop gained p.Q1033* 3 0 8.24E-06   45 Homozygous 
variant 
PAH c.3605A>T missense 
variant 
p.H1202L 2 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
31 Homozygous 
variant 
PAH c.4392dupT frameshift 
variant & splice 
region variant 
p.K1465* 2 0 Not found 
in ExAC 
  35 Homozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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23 M British 
c.3884T>G 
missense 
variant 
C Het   52 3.3 3 97 119 33 Yes 
Possible 
PVOD / 
PCH 
 
PDE5i + 
ERA + IV 
Prostanoid 
No  
c.3055_30
64delCTGA
CCAACG 
frameshift 
variant 
48 M Other 
c.4400dup
T 
frameshift 
variant 
C Het   46 6.4 3 116 120 45 No 
CT not 
available 
for 
analysis 
 
ERA + 
PDE5i + 
inhaled 
Prostanoid 
No  
c.1739dup
A 
frameshift 
variant 
38 F 
Other 
Asian 
c.2827A>G 
missense 
variant 
C Het    40 4.5 2    No 
CT not 
available 
for 
analysis 
 
ERA + 
PDE5i 
No  
c.4418_44
21delCAGA 
frameshift 
variant 
c.145-
2A>G 
splice 
acceptor 
variant 
Supplemental Table 7.  Phenotypic and genotypic description of patients with a clinical diagnosis of PAH with EIF2AK4 variants. mPAP –  mean pulmonary artery pressure, FC – functional 
class, FEV1 –  forced expiratory volume in 1s, FVC - forced vital capacity, KCO – transfer coefficient for carbon monoxide, PDE5i – phosphodiesterase type 5 inhibitor, ERA –  endothelin 
receptor antagonist, C Het – compound heterozygous, Hom – homozygous, Het – heterozygous, Unk – unknown  
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70 F British 
c.1392del
T 
frameshift 
variant 
C Het   76 6.6 3 101 127 33 Unk 
Possible 
PVOD / 
PCH 
 
PDE5i + 
ERA + 
inhaled 
Prostanoid 
No  
c.257+4A
>C 
splice 
region 
variant & 
intron 
variant 
36 F Indian 
c.3605A>
T 
missense 
variant 
Hom    44 2.7 3 73 83 40 Yes 
Possible 
PVOD / 
PCH 
 
ERA + 
PDE5i + 
inhaled 
Prostanoid 
No  
22 M Pakistani 
c.1795G>
C 
missense 
variant 
Hom   65 3.0 3 92 93 31 Yes PAH  
ERA + 
PDE5i + IV 
Prostanoid 
No Yes 
29 M Pakistani 
c.3097C>
T 
stop 
gained 
Hom   50 4.9 3 99 107 27 Unk PAH 
Sister 
died 
from 
PAH 
PDE5i No  
18 M 
Not 
stated 
c.1159_1
160delCT 
frameshift 
variant 
Hom   92  3 86 82 28 No 
Possible 
PVOD / 
PCH 
 
ERA + IV 
Prostanoid 
No  
25 F Pakistani 
c.1795G>
C 
missense 
variant 
Hom   57 5.6 3 82 87 33 No PAH  
PDE5i + 
ERA 
No  
Supplemental Table 7.  Phenotypic and genotypic description of patients with a clinical diagnosis of PAH with EIF2AK4 variants. mPAP –  mean pulmonary artery pressure, FC – functional 
class, FEV1 –  forced expiratory volume in 1s, FVC - forced vital capacity, KCO – transfer coefficient for carbon monoxide, PDE5i – phosphodiesterase type 5 inhibitor, ERA –  endothelin 
receptor antagonist, C Het – compound heterozygous, Hom – homozygous, Het – heterozygous, Unk – unknown  
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24 F 
Not 
stated 
c.2446C>
T 
stop 
gained 
Het 
(both 
on 
same 
allele) 
* 
  60 5.2 3 96 97 81 Unk 
CT not 
available 
for 
analysis 
Father 
and 
sister 
died of 
PAH 
Unk Unk  
c.3218G>
T 
missense 
variant 
39 F British 
c.1072_1
073dupG
T 
frameshift 
variant 
Het   54 3.0 2 87 98 72 No 
CT not 
available 
for 
analysis 
 ERA No  
40 F British c.44C>T 
missense 
variant 
Het  
c.4303-
50delT 
43 5.6 2 99 96 109 Unk 
Possible 
PVOD / 
PCH 
 ERA No  
44 M British 
c.2516T>
C 
missense 
variant 
Het 
c.853-
2A>G 
(splice 
acceptor 
variant) 
c.361-
180A>G 
53 3.8 3 102 98 54 Unk PAH  
PDE5i + 
ERA 
No  
25 F British 
c.3722A>
G 
missense 
variant 
Het     3 53 49 41 No 
CT not 
available 
for 
analysis 
 
PDE5i + 
ERA + IV 
Prostanoid 
No  
Supplemental Table 7.  Phenotypic and genotypic description of patients with a clinical diagnosis of PAH with EIF2AK4 variants. mPAP –  mean pulmonary artery pressure, FC – functional 
class, FEV1 –  forced expiratory volume in 1s, FVC - forced vital capacity, KCO – transfer coefficient for carbon monoxide, PDE5i – phosphodiesterase type 5 inhibitor, ERA –  endothelin 
receptor antagonist, C Het – compound heterozygous, Hom – homozygous, Het – heterozygous, Unk – unknown, *maternally inherited  
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66 F 
Not 
stated 
c.4646G>
A 
missense 
variant 
Het   44 2.1 3 79 100  Unk PAH  
PDE5i + 
ERA 
No  
72 M British 
c.1660G>
T 
missense 
variant & 
splice 
region 
variant 
Het   30 2.8 3    No PAH  
IV 
Prostanoid 
No   
59 F Other 
c.3711_3
713delGA
G 
inframe 
deletion 
Het   41 3.4 3 68 68 95 Unk PAH  
 ERA + 
PDE5i 
No  
48 F British 
c.3604C>
T 
missense 
variant 
Het 
c.2695C>T 
(stop 
gained) 
 57 4.4 4 90 100 61 Unk PAH  
 PDE5i + 
ERA 
No  
70 F 
Other 
White 
c.220G>A 
missense 
variant 
Het   42 5.4 2    Unk 
CT not 
available 
for 
analysis 
 ERA Unk  
Supplemental Table 7.  Phenotypic and genotypic description of patients with a clinical diagnosis of PAH with EIF2AK4 variants. mPAP –  mean pulmonary artery pressure, FC – functional 
class, FEV1 –  forced expiratory volume in 1s, FVC - forced vital capacity, KCO – transfer coefficient for carbon monoxide, PDE5i – phosphodiesterase type 5 inhibitor, ERA –  endothelin 
receptor antagonist, C Het – compound heterozygous, Hom – homozygous, Het – heterozygous, Unk – unknown  
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PAH patients 
with BMPR2 
mutations * 
PAH patients with no 
mutations in PAH 
associated genes 
PAH patients with 
EIF2AK4 heterozygous 
variants 
PAH patients with 
biallelic EIF2AK4 
mutations 
PVOD/PCH 
patients 
p 
n 64 255 3 7 5  
Age (years) 42 [31 - 52] 53 [39 - 67] 39 [32 - 40] 25 [23 - 38] 63 [27 - 76] <0.001 
Gender (n female [%]) 45 [70.3%] 179 [70.2%] 3 [100%] 2 [28.6%] 4 [80%] 0.161 
Ethnicity (n white Caucasian 
[%]) 
50 [78.1%] 226 [88.6%] 2 [66.7%] 2 [28.6%] 4 [80%] <0.001 
Digital clubbing (n [%]) 5 [13.2%] 3 [2.2%] 0 [0%] 2 [40%] 0 [0%] 0.004 
BMI 28 [25 - 33] 27 [24 - 31] 24 [24 - 25] 24 [21 - 27] 27 [24 - 32] 0.202 
Supplemental Table 8.  Phenotype summary of patients with preserved spirometry (FEV1 > 80 % predicted and FVC > 80 % predicted).  PAH patients with 
biallelic EIF2AK4 mutations are still younger at diagnosis and have a significantly reduced KCO compared to other groups. 
mPAP – mean pulmonary artery pressure, CO – cardiac output, PVR – pulmonary vascular resistance, FEV1 – forced expiratory volume in 1 second, FVC – 
forced vital capacity, KCO – transfer coefficient for carbon monoxide, BMI – body mass index.  * Also includes the 2 patients with heterozygous EIF2AK4 
variants and a BMPR2 mutation.  Data presented as median [IQR] unless indicated. Percentages were calculated using the number of patients for whom data 
were available as the denominator. 
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PAH patients 
with BMPR2 
mutations * 
PAH patients with no 
mutations in PAH 
associated genes 
PAH patients with 
EIF2AK4 heterozygous 
variants 
PAH patients with 
biallelic EIF2AK4 
mutations 
PVOD/PCH 
patients 
p 
mPAP (mmHg) 56 (15) 51 (18) 54 (8) 57 (20) 57 (7) 0.008 
CO (L/min) 3 [3 - 4] 4 [3 - 5] 5 [4 - 5] 5 [4 - 6] 3 [3 - 3] <0.001 
PVR (WU) 14 [10 - 18] 10 [7 - 14] 8 [7 - 9] 9 [8 - 15] 14 [11 - 19] <0.001 
Vasoresponders (n [%]) 0 [0%] 18 [21.7%] 0 [0%] 0 [0%]  0.016 
FEV1 (%pred) 97 [88 - 102] 93 [87 - 101] 96 [92 - 97] 97 [89 - 100] 98 [94 - 106] 0.525 
FVC (%pred) 102 [96 - 113] 103 [96 - 112] 97 [96 - 98] 107 [90 - 120] 109 [101 - 113] 0.704 
KCO (%pred) 80 [71 - 93] 68 [46 - 84] 81 [76 - 95] 33 [30 - 33] 33 [28 - 37] <0.001 
Resting SAO2 (%) 96 [94 - 98] 96 [93 - 98] 98 [98 - 99] 91 [90 - 92] 95 [91 - 95] 0.021 
SAO2 post walk test (%) 95 [90 - 98] 91 [85 - 96] 94 [87 - 96] 80 [75 - 84] 85 [85 - 88] <0.001 
Supplemental Table 8.  Phenotype summary of patients with preserved spirometry (FEV1 > 80 % predicted and FVC > 80 % predicted).  PAH patients with 
biallelic EIF2AK4 mutations are still younger at diagnosis and have a significantly reduced KCO compared to other groups. 
mPAP – mean pulmonary artery pressure, CO – cardiac output, PVR – pulmonary vascular resistance, FEV1 – forced expiratory volume in 1 second, FVC – 
forced vital capacity, KCO – transfer coefficient for carbon monoxide, BMI – body mass index.  * Also includes the 2 patients with heterozygous EIF2AK4 
variants and a BMPR2 mutation.  Data presented as median [IQR] unless indicated. Percentages were calculated using the number of patients for whom data 
were available as the denominator. 
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Supplemental Table 9.  Page 1/2 
Group  
All biallelic EIF2AK4 
mutation carriers 
PVOD with no EIF2AK4 
mutation 
p 
n  11 10  
Age (years)  26.8 [22.5 - 34.3] 68.3 [63.9 - 72.1] 0.001 
Gender (n female [%])  6 [54.5%] 5 [50.0%] 1.000 
Ethnicity (n white Caucasian 
[%]) 
 5 [45.5%] 9 [90.0%] 0.063 
mPAP (mmHg)  52 [47 - 63] 48 [42 - 57] 0.342 
PCWP (mmHg)  11 [7.5 - 12] 11.5 [9.0 – 12.2] 0.560 
FEV1 (% pred)  93.1 [82.8 - 98.5] 79.0 [72.3 – 91.0] 0.236 
FVC (% pred)  95.5 [84.6 - 108.5] 96.0 [73.0 – 101.0] 0.720 
KCO (% pred)  32.0 [28.7 – 33.0] 41.4 [36.8 – 54.0] 0.013 
Centrilobular ground glass 
opacification density 
None 2 [18.2%] 6 [60.0%] 
0.012 Subtle 2 [18.2%] 3 [30.0%] 
Present 7 [63.6%] 1 [10.0%] 
Supplemental Table 9.  Phenotypic and radiological characteristics of biallelic EIF2AK4 mutation carriers 
compared to patients with a clinical diagnosis of PVOD and no EIF2AK4 mutation. 
 
mPAP – mean pulmonary artery pressure, PCWP – pulmonary capillary wedge pressure, FEV1 – forced expiratory 
volume 1 s, FVC – forced vital capacity, KCO – transfer coefficient for carbon monoxide.  Data presented as 
median [IQR] unless stated. 
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Supplemental Table 9.  Page 2/2 
Group  
All biallelic EIF2AK4 
mutation carriers 
PVOD with no EIF2AK4 
mutation 
p 
Centrilobular ground glass 
opacification extent 
None 2 [18.2%] 7 [70.0%] 
0.007 
<5% 1 [9.1%] 1 [10.0%] 
5-25% 2 [18.2%] 1 [10.0%] 
25-50% 1 [9.1%] 1 [10.0%] 
50-75% 2 [18.2%] 0 [0.0%] 
75-100% 3 [27.3%] 0 [0.0%] 
Interlobular septal thickening 
None 7 [63.6%] 2 [20.0%] 
0.068 Subtle 0 [0.0%] 1 [10.0%] 
Present 4 [36.4%] 7 [70.0%] 
Mediastinal 
lymphadenopathy 
None 4 [36.4%] 2 [20.0%] 
0.635 
Present 7 [63.6%] 8 [80.0%] 
Pleural effusion 
None 11 [100.0%] 6 [60.0%] 
0.035 
Small 0 [0.0%] 4 [40.0%] 
Neovascularity 
None 10 [90.9%] 9 [90.0%] 
1.000 
Present 1 [9.1%] 1 [10.0%] 
CT diagnosis 
PAH 4 [36.4%] 3 [30.0%]  
Possible PVOD/PCH 7 [63.6%] 7 [70.0%]  
Supplemental Table 9.  Phenotypic and radiological characteristics of biallelic EIF2AK4 mutation carriers 
compared to patients with a clinical diagnosis of PVOD and no EIF2AK4 mutation. 
mPAP - mean pulmonary artery pressure, PCWP - pulmonary capillary wedge pressure, FEV1 - forced expiratory 
volume 1 s, FVC - forced vital capacity, KCO - transfer coefficient for carbon monoxide.  Data presented as 
median [IQR] unless stated. 
 
 26 
 
Group 
Time to 
assessment 1 
(days) 
n 
Change in 
6mwd (m) 
Change in 
FC 
Time to 
assessment 2 
(days) 
n 
Change in 
6mwd (m) 
Change in 
FC 
Number on 
prostanoid 
therapy 
before the 2nd 
assessment 
[%] 
PAH 
BMPR2 
357  
[314 - 386] 
21 
+69  
[20 - 100] 
-1  
[-1 - -1] 
1120  
[1055 - 1174] 
18 
+45  
[31 - 115] 
-1  
[-1 - -0.5] 
5 [23%] 
PAH 
biallelic 
EIF2AK4 
358  
[335 -388] 
9 
+28 
[-13 - 77] 
0  
[-1 - 0] 
1102 
[1090 – 1112] 
5 
+62  
[-8 - 132] 
0  
[0 - 0] 
1 [10%] 
PAH no 
mutation 
387  
[340 - 414] 
16 
+81  
[61 - 151] 
-1 
 [-1 - 0] 
1118  
[1105 - 1159] 
9 
+104  
[20 - 144] 
-1  
[-1 - 0] 
4 [17%] 
p 0.295  0.343 0.039 0.730  0.748 0.044 0.816 
Supplemental Table 10.  Response to pulmonary artery vasodilator therapies at 1 and 3 years after diagnosis compared to baseline. 6mwd - six-
minute walk test distance, FC - functional class.  Drop in number of patients between assessment 1 and 2 due to death, transplantation or lack of 
sufficient follow up time. Data presented as median [IQR] unless stated. 
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Variable 
Hazard Ratio  
[95% confidence interval] 
p 
PAH BMPR2 mutation* 0.148 [0.055 - 0.396] <0.001 
PAH no mutation* 0.179 [0.073 - 0.440] <0.001 
PVOD* 0.393 [0.075 - 2.065] 0.27 
Age at diagnosis 1.043 [1.033 - 1.053] <0.001 
Male gender 1.631 [1.222 - 2.179] <0.001 
Supplemental Table 11. Cox proportional hazards model assessing time to death.    
Patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations had an increased 
risk of death compared to other PAH patients. Number of patients = 858. Events = 194. 
* compared to the PAH biallelic EIF2AK4 mutation carriers 
 
 
Variable 
Hazard Ratio 
[95% confidence interval] 
p 
PAH BMPR2 mutation* 0.175 [0.066 - 0.462] <0.001 
PAH no mutation* 0.203 [0.083 - 0.501] <0.001 
PVOD* 0.840 [0.222 - 3.193] 0.798 
Age at diagnosis 1.036 [1.027 - 1.046] <0.001 
Male gender 1.542 [1.165 - 2.042] 0.002 
Supplemental Table 12.  Cox proportional hazards model assessing time to death or 
transplantation. Number of patients = 858. Events = 208. 
* compared to the PAH biallelic EIF2AK4 mutation carriers 
 
 
Variable 
Hazard Ratio 
[95% confidence interval] 
p 
PAH BMPR2 mutation* 0.376 [0.080 - 1.763] 0.215 
PAH no mutation* 0.456 [0.109 - 1.905] 0.282 
PVOD* 1.029 [0.133 - 7.953] 0.978 
Age at diagnosis 1.034 [1.020 - 1.046] <0.001 
Male gender 1.515 [1.000 - 2.296] 0.051 
Supplemental Table 13.  Sensitivity analysis including only prospectively recruited UK 
patients. Cox proportional hazards model assessing time to death. Number of patients = 
608. Events = 95. 
* compared to the PAH biallelic EIF2AK4 mutation carriers 
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Supplemental Figures 
 
Figure S1 
 
 
 
 
Supplemental Figure Legends: 
Figure S1: Kaplan – Meier survival curves showing survival time (time to death) for patients 
with a clinical diagnosis of PAH or PVOD.  
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